Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Fig. 2

Cyclin D1 levels in xenografts obtained from untreated and treated animals. a H1975- and b H1993-tumor-bearing animals were treated for 3 or 9 days with 50 or 100 mg/kg erlotinib, WZ4002, crizotinib, or vehicle. Surgically removed tumors were homogenized and tested for levels of cyclin D1, one of the main terminal mediators of EGFR signaling pathways, by western blot analysis at the indicated time and doses. Actin or tubulin served to ensure equal loading

Back to article page